Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience

Dilan A. Patel; Tanner M. Johanns; Kathryn Trinkaus; Nancy L. Bartlett; Nina Wagner-Johnston; Amanda F. Cashen

doi:10.1016/j.clml.2019.09.604

Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience

Dilan A. Patel, Tanner M. Johanns, Kathryn Trinkaus, Nancy L. Bartlett, Nina Wagner-Johnston, Amanda F. Cashen

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

In a retrospective study of 229 patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy regimens, we show that patients who experienced an infusion reaction had a higher probability of survival compared with those who did not.

Original language	English
Pages (from-to)	806-811
Number of pages	6
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	19
Issue number	12
DOIs	https://doi.org/10.1016/j.clml.2019.09.604
State	Published - Dec 2019

Keywords

Complement
Diffuse large B-cell lymphoma
Immunochemotherapy
Infusion reaction
Rituximab

Access to Document

10.1016/j.clml.2019.09.604

Cite this

@article{7c339dbbc8a5410a98e804f4696f9a68,

title = "Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience",

abstract = "In a retrospective study of 229 patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy regimens, we show that patients who experienced an infusion reaction had a higher probability of survival compared with those who did not.",

keywords = "Complement, Diffuse large B-cell lymphoma, Immunochemotherapy, Infusion reaction, Rituximab",

author = "Patel, {Dilan A.} and Johanns, {Tanner M.} and Kathryn Trinkaus and Bartlett, {Nancy L.} and Nina Wagner-Johnston and Cashen, {Amanda F.}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = dec,

doi = "10.1016/j.clml.2019.09.604",

language = "English",

volume = "19",

pages = "806--811",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

number = "12",

}

TY - JOUR

T1 - Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma

T2 - A Single Institution Experience

AU - Patel, Dilan A.

AU - Johanns, Tanner M.

AU - Trinkaus, Kathryn

AU - Bartlett, Nancy L.

AU - Wagner-Johnston, Nina

AU - Cashen, Amanda F.

PY - 2019/12

Y1 - 2019/12

N2 - In a retrospective study of 229 patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy regimens, we show that patients who experienced an infusion reaction had a higher probability of survival compared with those who did not.

AB - In a retrospective study of 229 patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy regimens, we show that patients who experienced an infusion reaction had a higher probability of survival compared with those who did not.

KW - Complement

KW - Diffuse large B-cell lymphoma

KW - Immunochemotherapy

KW - Infusion reaction

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85073822722&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.09.604

DO - 10.1016/j.clml.2019.09.604

M3 - Article

C2 - 31648954

AN - SCOPUS:85073822722

SN - 2152-2650

VL - 19

SP - 806

EP - 811

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 12

ER -

Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this